Oral sex can cause throat cancer by transmitting human papillomavirus (HPV) to the tissues at the back of the throat, where the virus can, in a small number of cases, trigger cancerous changes over many years. More than 80% of oropharyngeal cancers in the United States are now caused by HPV, making it a far bigger driver of these cancers than smoking or alcohol.
How HPV Reaches the Throat
HPV spreads through direct contact with infected skin or mucosal surfaces. During oral sex, the virus can transfer from a partner’s genital or anal area to the lining of the throat, particularly the tonsils and the base of the tongue. This region, called the oropharynx, has a type of tissue that appears especially vulnerable to HPV infection. The virus doesn’t need visible sores or symptoms to spread; most people who carry HPV have no idea they’re infected.
What HPV Does Inside Throat Cells
Once HPV infects cells in the oropharynx, it usually causes no harm. The immune system clears roughly 55% of new oral HPV infections within two years, and about 75% within five years. In most people, the infection is a temporary event with no lasting consequences.
In a minority of cases, the virus persists. HPV-16, the strain responsible for most HPV-related throat cancers, produces two proteins that hijack the cell’s normal safety controls. One protein disables p53, a molecule that acts as the cell’s emergency brake, stopping damaged cells from multiplying. The other protein disables a second safeguard called Rb, which normally keeps cells from entering their growth phase too quickly. With both of these checkpoints knocked out, infected cells can divide uncontrollably and accumulate genetic damage, eventually forming a tumor.
This process is slow. Data from studies tracking antibodies to HPV-16 suggest that the progression from initial infection to detectable cancer takes at least 10 years, and often longer. That long lag explains why HPV-related throat cancers typically appear in middle age, even though the triggering infection may have occurred decades earlier.
Who Is Most at Risk
Men are significantly more likely to develop HPV-related throat cancer than women. The incidence rate for oral and pharyngeal cancers is 17.5 per 100,000 in men, compared to 6.6 per 100,000 in women. The reasons for this gap aren’t fully understood, but differences in immune response to oral HPV infections and higher rates of oral HPV prevalence in men both play a role.
Several factors make it harder for the body to clear an oral HPV infection once it takes hold. Older age, living with HIV, and being male are all associated with slower clearance. Higher viral loads of HPV-16 at the time of detection also predict a lower chance the infection will resolve on its own. People whose infections are already established at the time they’re first tested clear the virus more slowly than those with newly acquired infections: only about 37% of established infections clear within two years, compared to 55% of new ones.
The number of oral sex partners also matters. Studies consistently show that a higher lifetime count of oral sex partners increases the likelihood of acquiring oral HPV and, by extension, the risk of oropharyngeal cancer.
Symptoms to Watch For
HPV-related throat cancers often produce subtle symptoms that are easy to dismiss. Common signs include a persistent sore throat, difficulty swallowing, unexplained ear pain on one side, hoarseness or voice changes, a lump in the neck, and unintended weight loss. A sore or lump that doesn’t heal after two to three weeks warrants medical attention, particularly if you have known risk factors.
One distinctive feature of HPV-positive throat cancers is that they frequently present as a painless lump in the neck, which is actually a swollen lymph node, before other symptoms become noticeable. Many patients are diagnosed after noticing this lump rather than because of throat pain.
HPV-Positive vs. Smoking-Related Throat Cancer
Throat cancers driven by HPV behave differently from those caused by tobacco and alcohol. HPV-positive oropharyngeal cancers tend to respond better to treatment and carry a significantly higher survival rate. They also tend to occur in younger, otherwise healthy patients who may have never smoked. Tobacco and alcohol remain the primary causes of cancers in the front of the mouth (the oral cavity), but HPV now dominates in the oropharynx, accounting for over 80% of cancers in that specific location.
How Vaccination Changes the Picture
The HPV vaccine prevents infection with the high-risk strains most responsible for cancer, including HPV-16 and HPV-18. It works by blocking the virus before it ever establishes an infection, which means it has no effect on infections someone already carries. Vaccination is recommended for preteens but can be given through age 26, and in some cases up to 45 after a conversation with a healthcare provider.
The impact on throat cancer rates is real but slow to materialize because of the long gap between infection and cancer. Projections from Johns Hopkins researchers estimate that the oropharyngeal cancer rate will nearly halve among people ages 36 to 45 between 2018 and 2045. By around 2033, vaccination is expected to prevent roughly 100 cases of oropharyngeal cancer per year in the U.S., with that figure increasing tenfold by 2045. But because older, largely unvaccinated generations will continue to develop these cancers, the overall national rate will barely budge for decades. The full benefits of widespread vaccination won’t be visible for 25 or more years.
For people beyond vaccination age, there is no approved screening test for oral HPV. Reducing the number of oral sex partners lowers exposure risk, and dental or medical exams can sometimes catch suspicious changes in the throat early, but no equivalent of a Pap smear exists for the oropharynx.